Merus Gains Momentum with Buy Ratings Amid Pharma Stock Surge

TL;DR Summary
The article discusses stocks that derive a significant portion of their revenue from government contracts, highlighting the potential risks and considerations for investors. It emphasizes the importance of understanding the financial dependencies of these companies on government spending, especially in light of potential policy changes or budget adjustments. The piece also mentions upcoming investment insights from experts like Guy Spier and analyst calls on major companies such as Nvidia, Apple, and Microsoft.
- DOGE coming: Beware these stocks that get the most revenue from the government CNBC
- Goldman says this pharma stock can rally nearly 70% thanks to key cancer treatment CNBC
- Merus (NASDAQ:MRUS) Earns "Buy" Rating from Needham & Company LLC MarketBeat
- Goldman Sachs Initiates Coverage of Merus N.V. (MRUS) with Buy Recommendation MSN
- Merus initiated with a Buy at Goldman Sachs TipRanks
Reading Insights
Total Reads
0
Unique Readers
20
Time Saved
0 min
vs 1 min read
Condensed
45%
132 → 72 words
Want the full story? Read the original article
Read on CNBC